Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Ceftriaxone. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR1I2 | O75469 | 6/20 | 0.80 |
| ▸ | PGR | P06401 | 3/20 | 0.80 |
| ▸ | PPARG | P37231 | 2/20 | 0.80 |
| ▸ | SLC22A6 | Q4U2R8 | 2/20 | 0.80 |
| ▸ | SLC22A8 | Q8TCC7 | 2/20 | 0.80 |
| ▸ | SLC22A11 | Q9NSA0 | 2/20 | 0.80 |
| ▸ | DAO | P14920 | 1/20 | 0.80 |
| ▸ | SNCA | P37840 | 1/20 | 0.80 |
| ▸ | CYP2J2 | P51589 | 1/20 | 0.80 |
| ▸ | ABCC4 | O15439 | 2/20 | 0.79 |
| ▸ | TDP1 | Q9NUW8 | 6/20 | 0.78 |
| ▸ | MAPT | P10636 | 5/20 | 0.78 |
| ▸ | APEX1 | P27695 | 3/20 | 0.78 |
| ▸ | HSD17B10 | Q99714 | 3/20 | 0.78 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.78 |
| ▸ | POLB | P06746 | 2/20 | 0.78 |
| ▸ | RECQL | P46063 | 2/20 | 0.78 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.78 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.78 |
| ▸ | BLM | P54132 | 1/20 | 0.78 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Ceftriaxone SCHEMBL2006477 | 1.00 | NR1I2 (0.80) | NR1I2PGRPPARGSLC22A6SLC22A8 | |
| Ceftriaxone SCHEMBL8619948 | 1.00 | NR1I2 (0.80) | NR1I2PGRPPARGSLC22A6SLC22A8 | |
| Ceftriaxone SCHEMBL8378294 | 1.00 | NR1I2 (0.80) | NR1I2PGRPPARGSLC22A6SLC22A8 | |
| Ceftriaxone SCHEMBL4897101 | 1.00 | NR1I2 (0.80) | NR1I2PGRPPARGSLC22A6SLC22A8 | |
| Ceftriaxone SCHEMBL30307091 | 1.00 | NR1I2 (0.80) | NR1I2PGRPPARGSLC22A6SLC22A8 | |
| Ceftriaxone SCHEMBL23354 | 1.00 | NR1I2 (0.80) | NR1I2PGRPPARGSLC22A6SLC22A8 | |
| Ceftriaxone SCHEMBL2006478 | 1.00 | NR1I2 (0.80) | NR1I2PGRPPARGSLC22A6SLC22A8 | |
| Ceftriaxone SCHEMBL4885115 | 0.99 | NR1I2 (0.79) | NR1I2PGRPPARGSLC22A6SLC22A8 | |
| Ceftriaxone SCHEMBL22635993 | 0.99 | NR1I2 (0.79) | NR1I2PGRPPARGSLC22A6SLC22A8 | |
| Ceftriaxone SCHEMBL150106 | 0.99 | NR1I2 (0.79) | NR1I2PGRPPARGSLC22A6SLC22A8 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20200056988-A1 | METHOD OF DETERMINING THE EFFICACY OF ANTIMICROBIALS | WISCONSIN ALUMNI RESEARCH FOUNDATION | 2020-02-20 | — | — | US | disclosed |
| EP-3534900-A1 | METHODS AND COMPOSITIONS FOR ATTENUATING ANTIBIOTIC RESISTANCE | Synthetic Biologics, Inc. (US) | 2019-09-11 | — | — | EP | disclosed |
| EP-3474885-A1 | MICROBIOME PROTECTION FROM ORAL ANTIBIOTICS | Synthetic Biologics, Inc. (US) | 2019-05-01 | — | — | EP | disclosed |
| WO-2018175414-A1 | BETA-LACTAMASE FORMULATIONS | SYNTHETIC BIOLOGICS, INC. (US) | 2018-09-27 | — | — | WO | disclosed |
| EP-3265119-A1 | SAFE AND EFFECTIVE BETA-LACTAMASE DOSING FOR MICROBIOME PROTECTION | Synthetic Biologics Inc. (US) | 2018-01-10 | — | — | EP | disclosed |
| WO-2018005606-A1 | MICROBIOME PROTECTION FROM ORAL ANTIBIOTICS | SYNTHETIC BIOLOGICS, INC. (US) | 2018-01-04 | — | — | WO | disclosed |
| EP-3261662-A1 | CARBAPENEMASES FOR USE WITH ANTIBIOTICS FOR THE PROTECTION OF THE INTESTINAL MICROBIOME | Synthetic Biologics Inc. (US) | 2018-01-03 | — | — | EP | disclosed |
| EP-3240800-A1 | CLOSTRIDIUM DIFFICILE TARGETING MOIETIES AND CONSTRUCTS COMPRISING SAID MOIETIES | C3 JIAN, LLC (US) | 2017-11-08 | — | — | EP | disclosed |
| EP-3236993-A1 | METHODS AND COMPOSITIONS FOR INHIBITING OR PREVENTING ADVERSE EFFECTS OF ORAL ANTIBIOTICS | Synthetic Biologics Inc. (US) | 2017-11-01 | — | — | EP | disclosed |
| EP-3166959-A1 | TARGETING PEPTIDES THAT BIND S. MUTANS, CONSTRUCTS COMPRISING SUCH PEPTIDES AND USES THEREOF | C3 Jian, Inc. (US) | 2017-05-17 | — | — | EP | disclosed |
| WO-2016105498-A1 | METHODS AND COMPOSITIONS FOR INHIBITING OR PREVENTING ADVERSE EFFECTS OF ORAL ANTIBIOTICS | SYNTHETIC BIOLOGICS, INC. (US) | 2016-06-30 | — | — | WO | disclosed |
| WO-2016007551-A1 | TARGETING PEPTIDES THAT BIND S. MUTANS, CONSTRUCTS COMPRISING SUCH PEPTIDES AND USES THEREOF | C3 JIAN, INC. (US) | 2016-01-14 | — | — | WO | disclosed |
| WO-2015100432-A2 | METHOD FOR PROPAGATING MICROORGANISMS WITHIN PLANT BIOREACTORS AND STABLY STORING MICROORGANISMS WITHIN AGRICULTURAL SEEDS | SYMBIOTA, INC. (US) | 2015-07-02 | — | — | WO | disclosed |
| WO-2014028745-A2 | A SYSTEM FOR COMPOUNDING AND PACKAGING READY TO RECONSTITUTE DRUG POWDERS OF SOLUTIONS TO A SOLUTION OR TO A SUSPENSION OR TO AN INJECTABLE | ARCHON PHARMACEUTICAL CONSULTING LLC (US) | 2014-02-20 | — | — | WO | disclosed |
| CN-102936285-A | Antibody for preventing and treating fish Edwardsiellaictaluri disease, preparation method and applications thereof | WUXI BEIRUIKANG BIOTECHNOLOGY CO LTD | 2013-02-20 | — | — | CN | disclosed |
| EP-2437596-A1 | SKIN TREATMENT COMPOSITIONS | Ex-Tek, LLC (US) | 2012-04-11 | — | — | EP | disclosed |
| CN-102292453-A | Transcription factor decoys | — | 2011-12-21 | — | — | CN | disclosed |
| WO-2011084882-A2 | METHODS AND COMPOSITIONS FOR ENHANCED IMMUNOLOGICAL THERAPY AND TARGETING OF GRAM-POSITIVE BACTERIA | CONTRAFECT CORPORATION (US) | 2011-07-14 | — | — | WO | disclosed |
| WO-2010141711-A1 | SKIN TREATMENT COMPOSITIONS | EX-TEK, LLC (US) | 2010-12-09 | — | — | WO | disclosed |
| WO-2010009735-A2 | COMBINATORIAL ANALYSIS AND REPAIR | DAKO DENMARK A/S (DK) | 2010-01-28 | — | — | WO | disclosed |